Literature DB >> 18799352

Adaptable dialog architecture and runtime engine (AdaRTE): a framework for rapid prototyping of health dialog systems.

L M Rojas-Barahona1, T Giorgino.   

Abstract

Spoken dialog systems have been increasingly employed to provide ubiquitous access via telephone to information and services for the non-Internet-connected public. They have been successfully applied in the health care context; however, speech technology requires a considerable development investment. The advent of VoiceXML reduced the proliferation of incompatible dialog formalisms, at the expense of adding even more complexity. This paper introduces a novel architecture for dialogue representation and interpretation, AdaRTE, which allows developers to lay out dialog interactions through a high-level formalism, offering both declarative and procedural features. AdaRTE's aim is to provide a ground for deploying complex and adaptable dialogs whilst allowing experimentation and incremental adoption of innovative speech technologies. It enhances augmented transition networks with dynamic behavior, and drives multiple back-end realizers, including VoiceXML. It has been especially targeted to the health care context, because of the great scale and the need for reducing the barrier to a widespread adoption of dialog systems.

Mesh:

Year:  2008        PMID: 18799352     DOI: 10.1016/j.ijmedinf.2008.07.017

Source DB:  PubMed          Journal:  Int J Med Inform        ISSN: 1386-5056            Impact factor:   4.046


  2 in total

1.  DREAM: Classification scheme for dialog acts in clinical research query mediation.

Authors:  Julia Hoxha; Praveen Chandar; Zhe He; James Cimino; David Hanauer; Chunhua Weng
Journal:  J Biomed Inform       Date:  2015-11-30       Impact factor: 6.317

Review 2.  Active assistance technology for health-related behavior change: an interdisciplinary review.

Authors:  Catriona M Kennedy; John Powell; Thomas H Payne; John Ainsworth; Alan Boyd; Iain Buchan
Journal:  J Med Internet Res       Date:  2012-06-14       Impact factor: 5.428

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.